ASX · IRX.AX
InhaleRx Limited
A$0.03A$0.00 (0.0%)
InhaleRx Limited’s quoted price sits in the lower half of its reported 52-week range, 41.67% below the high.
Loading market information…
ASX · BIT.AX · AUD
Stock price, earnings
Quote as of Oct 29, 2026, 10:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Biotron Limited’s quoted price sits in the lower half of its reported 52-week range, 60.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Biotron Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Biotron Limited is an Australian biotechnology firm dedicated to the creation and market introduction of small molecule therapies designed to combat a range of viral illnesses. Its flagship antiviral compound, BIT225, is currently undergoing Phase II clinical evaluations for addressing infections caused by SARS-CoV-2, HIV-1, and the hepatitis C virus. Established in 1999, the company operates from its main office in Sydney, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.03A$0.00 (0.0%)
InhaleRx Limited’s quoted price sits in the lower half of its reported 52-week range, 41.67% below the high.
A$0.01A$0.00 (0.0%)
Acrux Limited’s quoted price sits in the lower half of its reported 52-week range, 52.38% below the high.
$0.10$0.00 (0.0%)
Chimeric Therapeutics Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
A$0.08-A$0.00 (-5.06%)
Vectus Biosystems Limited’s quoted price sits in the lower half of its reported 52-week range, 83.52% below the high.
$0.21$0.00 (0.0%)
Zelira Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 50.78% below the high.
A$0.01+A$0.00 (+7.69%)
Bio-Gene Technology Limited’s quoted price sits in the lower half of its reported 52-week range, 71.43% below the high.
A$0.06A$0.00 (0.0%)
Global Health Limited’s quoted price sits in the lower half of its reported 52-week range, 54.17% below the high.
A$0.01A$0.00 (0.0%)
Imagion Biosystems Limited’s quoted price sits in the lower half of its reported 52-week range, 85.71% below the high.
